M. Ozcan Et Al. , "Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.," JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023
Ozcan, M. Et Al. 2023. Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16 .
Ozcan, M., Lee, S. T., Mensah, F., Modi, D., Fossa, A., Kim, W. S., ... Paszkiewicz-Kozik, E.(2023). Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.
Ozcan, MUHİT Et Al. "Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.," JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023
Ozcan, MUHİT Et Al. "Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023
Ozcan, M. Et Al. (2023) . "Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.
@article{article, author={MUHİT ÖZCAN Et Al. }, title={Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2023}